| Literature DB >> 20538092 |
Lev N Levanov1, Leonid E Matveev, Elena P Goncharova, Leonid R Lebedev, Alexander B Ryzhikov, Tatyana E Yun, Tatyana A Batanova, Alexander N Shvalov, Ivan K Baykov, Lyudmila N Shingarova, Michael P Kirpichnikov, Nina V Tikunova.
Abstract
Two chimeric antibodies (ch) 13D6 and 10C2 against the glycoprotein E of tick-borne encephalitis virus (TBEV) were constructed by fusing variable regions of murine monoclonal antibodies (Mabs) 13D6 and 10C2 to human constant regions. Monovalent analogues of these antibodies in format of single-chain antibodies (scFv or sc) were developed, as well. The ch13D6, ch10C2, sc13D6 and sc10C2 exhibited binding characteristics similar to parental Mabs. Only the ch13D6 and sc13D6 were able to neutralize TBEV infectivity in vitro. The in vitro neutralization provided by ch13D6 suggests that this antibody can be further developed into a potent prophylaxis and therapy for tick-borne encephalitis (TBE) infection. (c) 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20538092 DOI： 10.1016/j.vaccine.2010.05.060
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641